1. Home
  2. PTCT vs GRFS Comparison

PTCT vs GRFS Comparison

Compare PTCT & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PTC Therapeutics Inc.

PTCT

PTC Therapeutics Inc.

HOLD

Current Price

$82.28

Market Cap

5.7B

Sector

Health Care

ML Signal

HOLD

Logo Grifols S.A.

GRFS

Grifols S.A.

HOLD

Current Price

$7.13

Market Cap

5.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PTCT
GRFS
Founded
1998
1940
Country
United States
Spain
Employees
N/A
25247
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.7B
5.0B
IPO Year
2006
N/A

Fundamental Metrics

Financial Performance
Metric
PTCT
GRFS
Price
$82.28
$7.13
Analyst Decision
Buy
Hold
Analyst Count
17
2
Target Price
$80.65
$10.15
AVG Volume (30 Days)
2.2M
657.9K
Earning Date
05-07-2026
07-28-2022
Dividend Yield
N/A
1.80%
EPS Growth
264.48
N/A
EPS
N/A
N/A
Revenue
$264,734,000.00
N/A
Revenue This Year
N/A
$4.49
Revenue Next Year
$17.70
$6.42
P/E Ratio
N/A
$18.67
Revenue Growth
36.19
N/A
52 Week Low
$43.18
$6.96
52 Week High
$87.50
$11.14

Technical Indicators

Market Signals
Indicator
PTCT
GRFS
Relative Strength Index (RSI) 65.15 38.73
Support Level $73.41 N/A
Resistance Level $87.27 $7.73
Average True Range (ATR) 3.11 0.16
MACD 0.22 -0.01
Stochastic Oscillator 75.57 25.97

Price Performance

Historical Comparison
PTCT
GRFS

About PTCT PTC Therapeutics Inc.

PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.

About GRFS Grifols S.A.

Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.

Share on Social Networks: